Adcock Ingram

Adcock Ingram is a South African pharmaceutical manufacturer and healthcare-products company headquartered in Johannesburg. It develops, manufactures, markets and distributes prescription medicines, over-the-counter products, consumer-health goods and other healthcare offerings for both the private and public sectors. Its products reach patients and consumers through hospitals, doctors, pharmacies, wholesalers, retailers and public-health procurement channels. The business traces its origins to the EJ Adcock Pharmacy, established in Krugersdorp around 1890. From that initial retail pharmacy, the Tannenbaum family built a broader enterprise combining pharmacy operations with pharmaceutical and toiletry manufacturing. Adcock Ingram became the first pharmaceutical company listed on the Johannesburg Stock Exchange when it entered the exchange in 1950. Over subsequent decades, the company expanded through acquisitions and the development of several operating divisions, including pharmaceuticals, critical care, consumer products and wholesale activities. The company’s corporate development was closely connected with Tiger Brands. Although Adcock Ingram had been treated as a Tiger Brands subsidiary from 1978, the relationship also supported acquisitions during the 1980s and 1990s. These included interests and businesses associated with critical care, laboratories, pharmaceutical manufacturing and consumer products. A 1996 merger with Premier Pharmaceuticals strengthened Adcock Ingram’s position in the South African healthcare-products market. Further expansion included the acquisition of Steri-Lab in 2001 and Robertsons Homecare in 2003. Adcock Ingram began pursuing international opportunities during the 1990s. It established a small office in Leicester, England, in 1993 and created an international division in the mid-1990s to manage its first marketing initiatives outside South Africa. The international division was later discontinued as a separate transitional unit, while the company’s principal operating structure remained focused on its core businesses. Activities also extended toward Australia, although South Africa remained the company’s central commercial and operational base. By the middle of the 2000s, Adcock Ingram represented a substantial share of Tiger Brands’ revenue. Differences between Adcock Ingram’s portfolio and Tiger Brands’ broader strategic direction contributed to Tiger reducing its investment and ultimately divesting the business. Tiger Brands sold Adcock Ingram in 2008, after which Adcock Ingram was relisted on the Johannesburg Stock Exchange as an independent company. The company continues to operate as a listed South African pharmaceutical business, with a portfolio spanning prescription medicines, non-prescription healthcare and consumer-oriented products. Public sources do not provide a single stable catalogue covering every brand and market, so individual product availability should be verified through current company materials.

Adcock Ingram began as EJ Adcock Pharmacy in Krugersdorp around 1890. Krugersdorp was then a developing mining and pioneer town, and the pharmacy became the foundation for a much larger enterprise. Hyme Tannenbaum joined the pharmacy as an apprentice in the early twentieth century, followed by his brothers Jack, Len and Archie. The brothers eventually acquired the pharmacy and used it as the starting point for a nationwide retail-pharmacy network and a pharmaceutical and toiletry manufacturing business. The company’s growth transformed it from a local pharmacy into an integrated healthcare enterprise. Its activities came to include manufacturing, marketing, wholesale distribution and retail-related operations. Adcock Ingram was first listed on the Johannesburg Stock Exchange in 1950, making it the first pharmaceutical company to list on that exchange. The listing helped establish the company as a significant participant in South Africa’s formal pharmaceutical industry. During the period in which Adcock Ingram was associated with Tiger Brands, the business expanded through a series of acquisitions and investments. Tiger Brands’ involvement was established by 1978 and supported transactions in the 1980s, including the Mer-National division of Dow Chemicals Africa, a 40 percent interest in Baxter’s Critical Care Division, Restan Laboratories and the South African interests of Sterling Winthrop. In the 1990s, additional transactions involved Lepping, Laser, Pharmatech, Zurich Pharmaceuticals, Covan Pharmaceuticals and Salters. These deals broadened the company’s exposure to pharmaceutical manufacturing, critical care, laboratories and consumer products. Adcock Ingram also reorganized its operations as its portfolio grew. By 1995, the company had five divisions: critical care, pharmaceuticals, consumer products, wholesale products and an international division. The international division was created to oversee the company’s initial marketing efforts beyond South Africa. An office in Leicester, England, opened in August 1993 with two employees, reflecting the company’s intention to use the United Kingdom as a possible entry point into wider European markets. International activities also included Australia. The international division later disappeared as a separate transitional structure, leaving the principal domestic operating divisions. A merger with Premier Pharmaceuticals in 1996 positioned Adcock Ingram as a leading South African supplier of healthcare products. The company continued expanding in adjacent areas, acquiring the medical diagnostics business Steri-Lab in 2001 and Robertsons Homecare in 2003. By 2005, Adcock Ingram accounted for approximately half of Tiger Brands’ revenue, according to the cited historical account. Its growing scale also made the relationship with its parent more strategically important. Tiger Brands subsequently reduced its commitment to Adcock Ingram as tensions developed between the pharmaceutical company’s portfolio and Tiger’s wider strategic priorities. Tiger sold Adcock Ingram in 2008, followed shortly afterward by Adcock Ingram’s relisting on the Johannesburg Stock Exchange as an independent company. In the early 2000s, Mike Norris served as chief executive officer, while Jonathan Louw led the pharmaceuticals division from 2002 and succeeded Norris as chief executive in 2006. Louw remained in the role at least through 2013. Today, Adcock Ingram is described as a South African pharmaceutical manufacturer listed on the Johannesburg Stock Exchange. Its business covers prescription medicines, over-the-counter products and consumer health, with customers in both private and public healthcare. The company’s historical breadth has included hospital and critical-care activities, wholesale distribution, supplements, research supplies and consumer brands. Because product portfolios and registrations change by market and period, a current brand-by-brand inventory requires consultation of the company’s latest official materials.

1. 2008Independent relisting on the JSE

   Following Tiger Brands’ divestment, Adcock Ingram returned to the Johannesburg Stock Exchange as an independent company.

   Source
2. 2003Robertsons Homecare acquired

   Adcock Ingram expanded its consumer and homecare interests through the acquisition of Robertsons Homecare.

   Source
3. 2001Steri-Lab acquired

   The company added medical diagnostics capabilities through the acquisition of Steri-Lab.

   Source
4. 2000Sold to Tiger Brands

   Adcock Ingram became a wholly owned Tiger Brands subsidiary in a reported R3.4 billion transaction.

   Source
5. 1996Merger with Premier Pharmaceuticals

   The merger strengthened Adcock Ingram’s position as a major South African healthcare-products supplier.

   Source
6. 1995Five-division operating structure documented

   The company operated through critical care, pharmaceuticals, consumer products, wholesale products and an international division.

   Source
7. 1993Leicester office opened

   The company established a small office in Leicester, England, supporting its internationalization efforts.

   Source
8. 1978Association with Tiger Brands begins

   Adcock Ingram was treated as a subsidiary of Tiger Brands from 1978.

   Source
9. 1950First pharmaceutical company listed on the JSE

   Adcock Ingram became the first pharmaceutical company to list on the Johannesburg Stock Exchange.

   Source
10. 1890EJ Adcock Pharmacy established

    The business traces its origins to EJ Adcock Pharmacy in Krugersdorp, South Africa.

    Source

A broad-based South African pharmaceutical and healthcare-products company serving both private and public-sector markets.

• Prescription medicinesPrescription pharmaceuticals

  Prescription medicines are a core part of Adcock Ingram’s business. The company supplies products across multiple therapeutic areas through doctors, hospitals, pharmacies and public-sector healthcare channels. The available reference material does not establish a complete current list of individual prescription brands.

• Over-the-counter medicinesConsumer healthcare

  Adcock Ingram markets non-prescription products for common health and self-care needs. These products are distributed through pharmacies, retailers and other consumer channels, with availability varying by country and product registration.

• Critical-care productsHospital and critical care

  Critical care was one of the company’s documented operating divisions and reflects its supply of products used in hospital and acute-care settings. Specific current products are not enumerated in the available sources.

• Consumer-health productsConsumer health

  Consumer health includes products positioned for everyday health management and self-care outside the prescription-medicine channel. The company’s historical structure included a dedicated consumer-products division.

• Health supplementsSupplements and nutrition

  Health supplements are identified as part of the company’s broader healthcare portfolio. The available sources do not provide enough detail to specify individual supplement brands or formulations.

• Medical diagnosticsDiagnostics2001

  The acquisition of Steri-Lab in 2001 expanded Adcock Ingram into medical diagnostics. The reference material does not clarify the present scope of this activity.

• 2008Divestment and independent relistingM&A

  Tiger Brands reduced its investment as Adcock Ingram’s portfolio became less aligned with Tiger’s broader strategic direction.

  What changed. Tiger Brands sold Adcock Ingram, followed by Adcock Ingram’s relisting as an independent Johannesburg Stock Exchange company.

  Aftermath. Adcock Ingram resumed operating as an independently listed pharmaceutical company.

  Source
• 2000Sale to Tiger BrandsM&A

  Adcock Ingram was closely associated with Tiger Brands and was being integrated into the parent’s portfolio.

  What changed. Tiger Brands acquired Adcock Ingram as a wholly owned subsidiary.

  Aftermath. The relationship continued until Tiger Brands divested the business in 2008.

  Transaction value. R3.4 billion (2000 transaction)

  Source
• 1996Merge with Premier PharmaceuticalsM&A

  Adcock Ingram pursued scale in the South African healthcare-products market.

  What changed. The company merged with Premier Pharmaceuticals.

  Aftermath. The combined business was described as a leading supplier of healthcare products in South Africa.

  Source

• 2008Adcock Ingram is divested by Tiger Brands and relisted independently

  Tiger Brands divested Adcock Ingram after reducing investment in the business, and Adcock Ingram subsequently returned to the Johannesburg Stock Exchange as an independent listed company.

  M&A
  Source
• 2001Adcock Ingram acquires Steri-Lab

  The company expanded into medical diagnostics through the acquisition of Steri-Lab.

  M&A
  Source
• 2000Adcock Ingram becomes a wholly owned Tiger Brands subsidiary

  Adcock Ingram was sold to Tiger Brands in a transaction reported at R3.4 billion, making it a wholly owned subsidiary.

  M&A
  Source

1. Adcock Ingram
2. Adcock Ingram official website